PMID- 32173903
OWN - NLM
STAT- MEDLINE
DCOM- 20210713
LR  - 20210713
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 47
IP  - 6
DP  - 2020 Jun
TI  - Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma 
      cells through regulating ABCG2 expression.
PG  - 1049-1057
LID - 10.1111/1440-1681.13279 [doi]
AB  - Cisplatin (DDP) resistance limits its efficacy for retinoblastoma (Rb). 
      Hypoxia-inducible factor-1alpha (HIF-1alpha) has been shown to contribute to chemotherapy 
      resistance in tumours under hypoxic conditions. This study was designed to 
      explore the role and mechanism of long non-coding RNA (lncRNA) antisense 
      non-coding RNA in the INK4 locus (ANRIL) in regulating DDP resistance in Rb cells 
      under hypoxia and to validate whether HIF-1alpha was involved in this process. The 
      interaction between HIF-1alpha and the promoter of ANRIL was analyzed using ChIP 
      assay. Cell proliferation and apoptosis, as well as protein levels of drug 
      resistance-related proteins (ABCG2 and MDR1) were examined to evaluate DDP 
      resistance in Rb cells. The interactions between miR-328 and ANRIL as well as 
      miR-328 and ABCG2 were analyzed using dual-luciferase reporter assays. Upon 
      hypoxia, HIF-1alpha directly bound to the ANRIL promoter region to transcriptionally 
      activate ANRIL. The hypoxia-induced ANRIL promoted Rb cell resistance to DDP, as 
      evidenced by facilitation of cell proliferation, inhibition of cell apoptosis and 
      upregulation of ABCG2 and MDR1. Mechanistically, ANRIL promoted Rb cell 
      resistance to DDP by acting as a sponge of miR-328 to upregulate expression of 
      ABCG2, which was confirmed as a direct target of miR-328. Collectively, 
      hypoxia-induced ANRIL promotes DDP resistance in Rb cells by sponging miR-328 to 
      upregulate ABCG2 expression.
CI  - (c) 2020 John Wiley & Sons Australia, Ltd.
FAU - Yin, Xiaolong
AU  - Yin X
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Liao, Yujun
AU  - Liao Y
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Xiong, Weiwei
AU  - Xiong W
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Yuezhi
AU  - Zhang Y
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhou, Yue
AU  - Zhou Y
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Yang, Yang
AU  - Yang Y
AUID- ORCID: 0000-0001-7602-9676
AD  - Department of Pediatric Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Journal Article
DEP - 20200315
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (ABCG2 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily G, Member 2)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CDKN2B antisense RNA, human)
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - 0 (MIRN328 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Long Noncoding)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily G, Member 2/genetics/*metabolism
MH  - Antineoplastic Agents/*pharmacology
MH  - Cell Line, Tumor
MH  - Cisplatin/*pharmacology
MH  - *Drug Resistance, Neoplasm
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/genetics/metabolism
MH  - MicroRNAs/genetics/metabolism
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Retinal Neoplasms/*drug therapy/genetics/metabolism/pathology
MH  - Retinoblastoma/*drug therapy/genetics/metabolism/pathology
MH  - Tumor Hypoxia
OTO - NOTNLM
OT  - ABCG2
OT  - ANRIL
OT  - cisplatin resistance
OT  - miR-328
OT  - retinoblastoma
EDAT- 2020/03/17 06:00
MHDA- 2021/07/14 06:00
CRDT- 2020/03/17 06:00
PHST- 2019/12/20 00:00 [received]
PHST- 2020/02/08 00:00 [revised]
PHST- 2020/02/09 00:00 [accepted]
PHST- 2020/03/17 06:00 [pubmed]
PHST- 2021/07/14 06:00 [medline]
PHST- 2020/03/17 06:00 [entrez]
AID - 10.1111/1440-1681.13279 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2020 Jun;47(6):1049-1057. doi: 
      10.1111/1440-1681.13279. Epub 2020 Mar 15.